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Abstract
The multikinase inhibitor sorafenib is the first oral agent to show activity against human hepatocellular carcinoma
(HCC). Although the clinical application of sorafenib has shown good tolerability in the studied populations, it also
causes multiple human dose-limiting toxicities. Thus, there is a strong need to reduce the overall dose of sorafe-
nib. We have reported that the epidermal growth factor receptor variant III (EGFRvIII) expression can decrease the
sensitivity of HCC cells to chemotherapeutic drugs. Therefore, we sought to explore whether EGFRvIII can affect
the sensitivity of HCC cells to sorafenib. In this study, we observed that EGFRvIII expression significantly de-
creased the sensitivity of HCC cells to sorafenib. To enhance the antitumor effect and reduce the overall dose
of sorafenib, we evaluated the combined effects of CH12, a monoclonal antibody against EGFRvIII, and sorafenib
on the growth of HCC cells expressing EGFRvIII in vitro and in vivo. The results showed that, when CH12 was
combined with sorafenib, the tumor growth suppression effect was significantly increased, and the concentration
of sorafenib required for growth inhibition was substantially reduced. Mechanistically, the combination could more
noticeably downregulate the phosphorylation of constitutively active extracellular signal–regulated kinase (ERK),
Akt (Thr308), and signal transducer and activator of transcription 3 (STAT3) than sorafenib alone. Collectively, these
findings demonstrate that CH12 interacts additively with sorafenib to strongly inhibit the tumor growth of HCC
xenografts expressing EGFRvIII by enhancing the sorafenib-mediated inhibition of the MEK/ERK, phosphoinositide
3-kinase/AKT, and STAT3 pathways.
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Introduction
Hepatocellular carcinoma (HCC) is the fifth most common cancer
and the third leading cause of cancer-related death worldwide [1,2].
Over the past decades, the incidence of HCC has increased world-
wide, especially in eastern Asia and sub-Saharan Africa [1,3]. HCC
is clinically characterized by its invasiveness, poor prognosis, and lim-
ited therapeutic opportunities. At present, surgery is the most effective
treatment for HCC. However, tumor recurrence after a curative liver
resection is high [4]. For advanced stage disease, systemic pharmaco-
therapy is usually the final and main treatment. Previous clinical inves-
tigations have shown that traditional systemic chemotherapy cannot
provide survival benefits for patients with HCC [2]. Thus, there is a
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strong need for new, effective, and well-tolerated treatment strategies
for this aggressive disease. Sorafenib was the first successful molecular
targeted therapy for advanced HCC, as demonstrated in The Sorafenib
Hepatocellular Carcinoma Assessment Randomized Protocol trial,
and it offers hope for improving the treatment of HCC [5].
Sorafenib (Nexavar), an oral multiple kinase inhibitor, was approved
by the Food and Drug Administration to treat advanced HCC and
is the first clinically approved targeted drug therapy for HCC [6,7].
Sorafenib shows remarkable inhibition of the serine-threonine kinase
Raf, which is part of the Ras/MEK/ERK signaling pathway, and sup-
presses several receptor tyrosine kinases involved in tumor progression
and tumor angiogenesis, including vascular endothelial growth factor
receptors 2 and 3, platelet-derived growth factor receptor, FLT3, and
c-KIT [7]. Although the clinical application of sorafenib has shown
good tolerability in the studied populations, it also causes multiple
human dose-limiting toxicities, including anorexia, gastrointestinal
bleeding, and hand-foot syndrome, and many patients need to perma-
nently withdraw from treatment because of severe skin toxicity [8].
Therefore, reducing the overall dose of sorafenib is a desirable goal.
Although the epidermal growth factor receptor (EGFR) has been
successfully targeted for cancer therapy [9], for example, by the mono-
clonal antibody cetuximab (C225, Erbitux) [10,11], the presence of
EGFR gene mutations may result in a limited clinical response to
EGFR-targeting therapies in HCC patients. The most common EGFR
variant is EGFRvIII (also called de2-7 EGFR) [12], which can promote
tumor cell growth in vitro and in vivo [13]. EGFRvIII has been found
in head and neck squamous cell carcinoma, non–small cell lung carci-
noma, breast cancer, glioma, ovarian carcinoma, and HCC but has not
been detected in normal tissue [13–17]. Recently, we also observed its
expression in liver cancer cell lines, such as SMMC-7721 cells [18].
Because EGFRvIII expression can decrease the sensitivity of HCC
cell lines to chemotherapeutic drugs, such as 5-fluorouracil [18], it may
also account for the limited therapeutic effect of sorafenib. CH12, an
anti-EGFRvIII monoclonal antibody developed in our laboratory, can
preferentially bind to EGFRvIII and significantly inhibit the growth of
Huh-7–EGFRvIII and SMMC-7721 xenografts in vivo, with a growth
inhibition ratio much higher than cetuximab [19]. We hypothesized
that CH12 may enhance the sorafenib-mediated growth inhibition
of HCC xenografts expressing EGFRvIII, and we found that com-
bining sorafenib with CH12 more effectively inhibits HCC cell line
growth than either agent alone. These results lay the groundwork
for possible future clinical evaluation of this drug combination as an
HCC therapy.
Materials and Methods
Cell Culture
The human HCC cell lines Huh-7, Huh-7–EGFRvIII (Huh-7 cells
with exogenous EGFRvIII overexpression [18]) and SMMC-7721
(Chinese Academy of Science, Shanghai, China) were used. All of
the cell lines were maintained in Dulbecco modified Eagle medium
(DMEM) supplemented with 10% fetal bovine serum in a humidified
atmosphere of 95% air and 5% CO2 at 37°C.
Drugs
Sorafenib (BAY 43-9006) was purchased from Toronto Research
Chemicals, Inc (Canada). For in vitro studies, sorafenib was dissolved
in dimethyl sulfoxide (Sigma, St Louis, MO) at various concentra-
tions. For in vivo studies, sorafenib was formulated at a concentration
four-fold that of the highest dose in a cremophor EL–ethanol (50:50)
solution. This four-fold stock solution was prepared fresh daily. The
final dosing solutions were prepared on the day of use by diluting the
stock solution to one-fold with endotoxin-free distilled water and
vortexing immediately before dosing. The chimeric mAb CH12 (IgG1)
was produced in dihydrofolate reductase–deficient CHODG44 cells as
described previously [19]. The chimeric mAb C225 were purchased
from Merck (La Jolla, CA).
In Vitro Cell Proliferation Assay
The effect of the test agents on cell viability was assessed with the
CCK-8 assay. The cells (2000 per well) were seeded. After 24 hours,
the cells were exposed to various concentrations of the test agents in
DMEM with 10% fetal bovine serum (FBS) for 48 hours. The con-
trols received the dimethyl sulfoxide vehicle at a concentration equal
to that of drug-treated cells. After 48 hours, cell proliferation was
measured using a CCK-8 kit (Dojindo Laboratories, Rockville,
MD). CCK-8 solution (10 μl) was added to 100 μl of culture media,
and the optical density was measured at 450 nm. Three independent
experiments were performed.
Immunoblot Analysis
The cells were seeded and incubated in six-well plates in DMEM
with 10% FBS for 24 hours and exposed to various concentrations of
CH12, sorafenib, or a combination in 2% FBS-supplemented
DMEM for 24 hours. The cell lysates were then collected. The tumor
tissues were surgically excised and frozen in liquid nitrogen. Then the
tissues were homogenized in tumor lysis buffer, and the lysates were
collected. The proteins were quantified using the BCA Kit (Pierce,
Rockford, IL). The proteins (20 μg) were separated with 10% SDS-
PAGE gels and transferred to nitrocellulose membranes (Millipore
Billerica, MA). The membranes were blocked with 5% skim milk
and incubated overnight at 4°C with primary antibodies. The following
antibodies were used: mAb 12H23, anti–phospho-EGFR (Tyr1068)
(Abcam, Cambridge, United Kingdom) and anti-GAPDH (Kang-
Chen Bio-tech, Shanghai, China) antibodies. The anti–phosphor-
ERK, anti-ERK1, anti–phospho-Akt (Thr308), anti–phospho-Akt
(Ser473), anti-Akt, anti–phospho-MEK, anti-MEK, anti–Bcl-xL, and
anti-p27 antibodies were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA). The other antibodies, including anti-STAT3 (signal
transducer and activator of transcription 3) and anti–phospho-STAT3
(p-STAT3; Tyr705), were obtained from Cell Signaling (Cell Signaling
Technology, Danvers, MA). The immune complexes were detected
through incubation of the membrane with horseradish peroxidase–
conjugated goat antimouse antibody or goat antirabbit antibody (Santa
Cruz Biotechnology) for 1 hour at room temperature and subsequent
exposure of the membrane to enhanced chemiluminescence reagents
(Pierce, Thermo Scientific, Rockford, IL).
In Vivo Antitumor Effects
Huh-7–EGFRvIII cells (3 × 106) were subcutaneously injected into
4- to 6-week-old nude mice. When the tumor volumes reached an
average of approximately 100 mm3, mice were randomly assigned to
one of the following treatment groups (n = 6 for each group): 1) a daily
oral dose of vehicle solution and thrice-weekly intraperitoneal injections
of phosphate-buffered saline (PBS; control group), 2) a daily oral dose of
sorafenib at 10 mg/kg (sorafenib group), 3) intraperitoneal injections
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of CH12 (25 mg/kg) thrice weekly (CH12 group), and 4) a daily oral
dose of sorafenib at 10mg/kg plus an intraperitoneal injection of CH12
at 25 mg/kg thrice weekly (sorafenib-plus-CH12 group). All of the
mice were treated for 2 weeks. The tumor volumes were measured
every other day in two dimensions with Vernier calipers. The tumor
volumes were calculated using the following formula: length × width2 ×
0.5. Two weeks after the final treatment, mice were anesthetized and
sacrificed through cervical dislocation. The tumors were surgically excised
and weighed. Tumor tissues from the in vivo experiments were col-
lected for Western blot analysis and immunohistochemical studies.
Mice were manipulated and housed according to protocols approved
by the Shanghai Medical Experimental Animal Care Commission.
Immunohistochemical Analysis
To assess angiogenesis and cell proliferation in tumors, formalin-
fixed, paraffin-embedded tumor tissues were immunostained using
rat antimouse CD34 (Abcam) and anti–Ki-67 (Santa Cruz Biotechnol-
ogy). After deparaffinization and rehydration, the tissue sections were
incubated with 3% hydrogen peroxide in methanol to quench endog-
enous peroxidase. The sections were blocked for 30 minutes with 1%
bovine serum albumin and incubated overnight with the primary anti-
body at 4°C. Sections were then washed with PBS and incubated with
an horseradish peroxidase–conjugated secondary antibody for 45 min-
utes. Then, the products were visualized using a diaminobenzidine
staining kit (Tiangen Biotech, Beijing, China) and counterstained in
hematoxylin. The measurement of Ki-67 labeling index and micro-
vessel density was performed as described previously [16].
TUNEL Assay
Tumor tissue sections were first deparaffinized and rehydrated and
were then incubated with proteinase K (20 μg/ml) for 20 minutes at
37°C. After several washes with PBS, the sections were incubated
with TUNEL assay buffer (Beyotime Biotechnology, Nanjing, China)
for 1 hour at 37°C in the dark. Then, the slides were rinsed in PBS
three times and visualized under a Zeiss LSM confocal microscope
(Carl Zeiss, Jena, Germany). TUNEL-positive cells were counted at
×400 magnification. The apoptotic index was calculated as a ratio of
apoptotic cell number to the total cell number in each field.
Statistical Analysis
All data are presented as the mean ± SE. Data were examined using
an analysis of variance (ANOVA) and the least significant differences
method for multisample comparisons. P < .05 was considered statisti-
cally significant.
Results
EGFRvIII Expression Decreases the Sensitivity of HCC Cell
Lines to Sorafenib
To assess whether EGFRvIII expression affected the sensitivity of
HCC cell lines to sorafenib, we first investigated the inhibitory effect
of different concentrations of sorafenib (1, 2, 3, 5, and 7.5 μM) on
Huh-7, Huh-7–EGFRvIII, and SMMC-7721 cells. As shown in
Figure 1A, the Huh-7 cells were more sensitive to sorafenib than
the Huh-7–EGFRvIII and SMMC-7721 cells, both of which expressed
EGFRvIII [18], especially in the low-concentration groups.
Previous studies indicated that sorafenib suppressed tumor growth
in the HCC model partly via inhibiting the Raf/MEK/ERK pathway
[20] and STAT3 [21]. STAT3 is constitutively elevated inmany human
solid tumors and hematologic malignancies and has been shown to
actively participate in cell growth and survival [22]. To better under-
stand how EGFRvIII induces sorafenib resistance at a molecular level,
we examined the effects of sorafenib on the phosphorylation of EGFR
(p-EGFR), ERK (p-ERK), and STAT3 (p-STAT3). In the absence of
sorafenib treatment, the p-EGFR, p-ERK, and p-STAT3 levels were
higher in Huh-7–EGFRvIII cells than in Huh-7 cells. After sorafenib
treatment, the p-EGFR, p-ERK, and p-STAT3 levels were more notice-
ably downregulated in Huh-7 cells than in Huh-7–EGFRvIII cells
(Figure 1B). Together, these data indicate that EGFRvIII may confer
at least partial resistance to sorafenib in HCC cell lines and that the
higher levels of ERK and STAT3 phosphorylation may be one of the
mechanisms underlying the lower sensitivity of EGFRvIII-positive
HCC cells to sorafenib.
Inhibition of Huh-7, Huh-7–EGFRvIII, and SMMC-7721
Cell Growth by Sorafenib Plus CH12
To investigate the combined effects of CH12 and sorafenib on
HCC cells, we examined the effects of both drugs on cell viability
of Huh-7, Huh-7–EGFRvIII, and SMMC-7721 cells. At the same
time, we also evaluated the effects of sorafenib in combination with
EGFR inhibitor C225 (cetuximab) on these cells. The cell viability
was measured with the CCK-8 assay. Our data illustrated that the
combination of CH12 and sorafenib enhanced the antitumor effects
of sorafenib in a dose-dependent manner on Huh-7–EGFRvIII and
Figure 1. EGFRvIII expression decreases the sensitivity of Huh-7–
EGFRvIII and SMMC-7721 cell lines to sorafenib. (A) HCC cells
were exposed to drugs at different concentrations (1, 2, 3, 5,
and 7.5 μM) for 48 hours, and cell viability was analyzed with
CCK-8. (B) Huh-7 and Huh-7–EGFRvIII cells were treated with 1 or
3 μM sorafenib in 2% FBS-supplemented DMEM for 24 hours,
and the cell lysates were collected. The expression levels of phos-
phorylated EGFR, ERK, and STAT3 were examined.
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SMMC-7721 cells expressing EGFRvIII. However, there were no
obvious additive antitumor effects on Huh-7 cells when sorafenib
was combined with CH12 (Figure 2). The possible interpretation is
that CH12 barely bind to Huh-7 cells in vitro [19]. The combination
of C225 and sorafenib exhibited the enhanced antitumor effects on
Huh-7 and SMMC-7721 cells. However, sorafenib in combination
with C225 exerted a lower growth inhibitory effect on SMMC-
7721 cells than sorafenib in combination with CH12. Moreover,
the combined effects of C225 and sorafenib were not observed on
Huh-7–EGFRvIII cells (Figure 2).
Reduction of p-EGFR, p-Akt (Thr308), and p-STAT3 Levels
and Inhibition of MEK/ERK Signaling by Sorafenib Plus
CH12 In Vitro
Next, we investigated the mechanisms underlying the reduction in
cell proliferation caused by the combination of sorafenib plus CH12.
Previous reports have suggested that the constitutively active kinase
activity and autophosphorylation of the carboxyl terminus of EGFR-
vIII can promote tumor cell growth in vitro and in vivo [13,18].
Therefore, we examined the total and phosphorylated EGFR levels in
Huh-7–EGFRvIII and SMMC-7721 cells treated with various does of
sorafenib, CH12, or the combination throughWestern blot analysis. In
the two cell lines, we observed a dramatic down-regulation of p-EGFR
in the combination groups (Figure 3).
Previous studies have indicated that sorafenib and CH12 can both
downregulate the phosphorylation of ERK and Akt in HCC xeno-
grafts [19,20]. Therefore, we investigated the p-ERK and p-Akt
(Thr308) levels in Huh-7–EGFRvIII and SMMC-7721 cells treated
with sorafenib and CH12. As shown in Figure 3, although sorafenib
dose-dependently inhibited ERK phosphorylation, its combination
with CH12 led to a more noticeably reduction in p-ERK levels.
The p-Akt (Thr308) levels were also considerably inhibited by the
sorafenib-plus-CH12 combination treatment compared with the single-
agent treatment. Recent studies indicated that sorafenib, as a single
agent, could increase the Akt (Ser473) phosphorylation, and the Akt
(Ser473) may be one of the main mediators of sorafenib resistance
[23,24].Herewe also detected the levels of p-Akt (Ser473). Intriguingly,
in Huh-7–EGFRvIII cells, sorafenib alone caused the upregulated the
levels of p-Akt (Ser473), but in SMMC-7721 cells, we did not find an
obvious change in p-Akt (Ser473). When sorafenib was combined with
CH12, the levels of p-AKT (Ser473) were slightly downregulated in
both Huh-7–EGFRvIII and SMMC-7721 cells compared with single-
agent sorafenib treatment. Total ERK and Akt levels were unchanged
in both cell lines (Figure 3).
To verify whether the therapeutic effect was dependent on the down-
regulation of p-STAT3 by the combination of sorafenib and CH12, we
further assayed the expression of STAT3 in treatedHCC cells. As shown
in Figure 3, combination treatment could reduce STAT3 phosphory-
lation in Huh-7–EGFRvIII and SMMC-7721 cell lines, although the
phosphorylation levels of STAT3 were downregulated to a greater
degree in SMMC-7721 cells than in Huh-7–EGFRvIII cells, whereas
there was no obvious decrease when both cell lines were treated with
sorafenib or CH12 alone. The total STAT3 protein level was not
affected by sorafenib and CH12 treatment.
Additive Effect of Sorafenib Plus CH12 on Huh-7–EGFRvIII
Xenograft Tumor Growth In Vivo
To investigate whether the combined effect of sorafenib and CH12
in HCC cell lines expressing EGFRvIII had potential clinical implica-
tions, we assessed the in vivo effect of sorafenib plus CH12 on the
growth of HCC xenograft tumors. The clinical recommended daily
dose of sorafenib is 800 mg, and in a previous report, the dosage of
sorafenib used in mice bearing HCC models was generally 30 mg/kg
per day [20]. Because CH12 enhanced the antitumor effect and
reduced the dosage of sorafenib in the in vitro cytotoxicity assay,
we used a lower dosage of sorafenib (10 mg/kg per day) to test the
Figure 2. The growth inhibition of Huh-7, Huh-7–EGFRvIII, and SMMC-7721 cells by CH12, C225 (100 μg/ml), sorafenib (1, 2, or 3 μM), or
the combination. HCC cells were exposed to the drugs for 48 hours and were analyzed with CCK-8. Data are expressed as the percentage
inhibition of cell growth. Bars, SD.
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combined effect of sorafenib and CH12 on Huh-7–EGFRvIII xeno-
grafts. Tumor-bearing mice were treated with vehicle or 10 mg/kg per
day sorafenib orally for 14 days or 25 mg/kg per day CH12 intra-
peritoneally three times a week for 2 weeks. All of the animals toler-
ated the treatments well, without observable signs of toxicity, and had
stable body weights during the study.
As shown in Figure 4C , tumor growth was considerably inhibited
by treatment with sorafenib plus CH12 at day 21 after tumor cell’s
inoculation (vs sorafenib or CH12 treatment alone, P < .05). The
inhibitory ratios of sorafenib, CH12, and the combination on day 30
were 22.3%, 51.4%, and 85.4%, respectively (Figure 4D). Tumor
weight was also measured at the end of the study. Our data showed that
the cotreatment of CH12 and sorafenib at a low dosage, which was
minimally effective when used as a single agent, reduced the tumor
weight significantly when given as a combination (vs sorafenib or
CH12 treatment alone, P < .05; Figure 4E ). Together, these data
indicate that the combination of sorafenib and CH12 exhibits better
antitumor activity in vivo.
Combined Treatment of Sorafenib and CH12 Reduced the
Cell Proliferation and Angiogenesis and Enhanced Apoptosis in
Huh-7–EGFRvIII Tumors
To further elucidate the mechanism underlying the in vivo growth
suppression caused by CH12 and sorafenib, we determined the pro-
liferative rate and angiogenesis of tumors in the control and treated
mice. In xenograft tumors, the proliferative index, measured with
Ki-67 staining, was significantly lower for the CH12-plus-sorafenib
combination–treated tumors than the vehicle-treated control tumors
(P < .01; Figure 5, A and B) and CH12- or sorafenib-treated tumors
(P < 05; Figure 5, A and B).
The extent of tumor vascularization was analyzed by immunostain-
ing of tumors from treated and control groups for CD34. Fewer
CD34-positive tumor microvessels were observed in the CH12-plus-
sorafenib group than in the other three groups (P < .05; Figure 5, C
and D). In addition, analysis of the apoptotic index through TUNEL
staining showed a significant increase in the number of apoptotic cells
in the group of sorafenib in combination with CH12 as compared with
the other three groups (P < .01; Figure 6).
Molecular Mechanisms Underlying the Additive Antitumor
Effect of Sorafenib Plus CH12 In Vivo
To understand the molecular events occurring in sorafenib-plus-
CH12–treated tumors, some key signaling molecules were examined
with Western blot analysis (Figure 7). As Figure 7 shows, compared
with the other three groups, the p-EGFR, p-ERK, p-MEK, p-Akt
(Thr308), and p-STAT3 levels were dramatically downregulated in
the CH12-and-sorafenib combination therapy group, which is consis-
tent with the results in vitro. However, we did not observe the obvious
change in p-Akt (Ser473) in the combination treatment of sorafenib
with CH12. In our previous study, CH12 treatment enhanced the
expression of p27, a negative regulator of the cell cycle, and reduced
the expression of Bcl-xL, which can inhibit apoptosis [19]. Therefore,
in this study, we also determined the p27 and Bcl-xL status in the
CH12-plus-sorafenib–treated tumors. We found that Bcl-xL was
more noticeably downregulated, whereas the up-regulation of p27
was not obvious in the combination therapy group compared with
the CH12- or sorafenib-treatment-alone groups (Figure 7).
Discussion
HCC is a heterogeneous malignancy with complex carcinogenesis
[20]. Patients who have advanced HCC are not amenable to treat-
ment with surgery, local ablation, or regional therapy. The chemo-
therapy for advanced HCC is still unsatisfactory. These issues have
led to a search for novel approaches for HCC therapy, including the
targeting of the EGFR (e.g., with erlotinib and cetuximab), vascular
endothelial growth factor (bevacizumab), or the Raf/MEK/ERK
pathway (sorafenib). The multikinase inhibitor sorafenib is the first
oral agent to show clinical activity against human HCC. Although
the clinical application of sorafenib has shown good tolerability in
the studied populations, it also causes multiple toxicities, and a large
percentage of patients have to be treated with a reduced dose or stop
taking the drug for this reason [25]. This toxicity was the stimulus
for us to search for agents that could act additively with sorafenib to
enhance its HCC growth inhibition, which could reduce the dosage
of sorafenib and thus decrease its adverse effects.
Figure 3. Dose-dependent effects of sorafenib plus CH12 on the
activation of EGFR, ERK, Akt, and STAT3 in Huh-7–EGFRvIII cells
(A) and SMMC-7721 cells (B). The cells were exposed to the drugs
and were then lysed. A total of 20 μg of soluble protein was sep-
arated through SDS-PAGE. Protein levels were detected with
Western blot analysis. GAPDH was used as the loading control.
Neoplasia Vol. 14, No. 6, 2012 The Additive Effect of Sorafenib Plus CH12 on HCC Yang et al. 513
Recently, some studies reported that sorafenib in combination
with EGFR inhibitors had synergistic antitumor activity in human
non–small cell lung cancer, colorectal cancer, and HCC cells [26,27].
The possible mechanisms were that sorafenib could inhibit the ac-
tivation of vascular endothelial growth factor–dependent signal-
ing, which is responsible for the intrinsic resistance to anti-EGFR
therapies [26], or EGFR inhibitors could restrict the activation of
p-ERK and p-AKT, which leads to sorafenib resistance [27]. As
demonstrated in our previous report, EGFRvIII expression can de-
crease the sensitivity of HCC cell lines to a chemotherapeutic drug
[18]. In this study, we also observed that EGFRvIII expression re-
duced the sensitivity of HCC cells to sorafenib. Recently, we devel-
oped a mouse-human chimeric monoclonal IgG1 antibody CH12,
which is a promising biotherapeutic agent for cells expressing
EGFRvIII. CH12, which inhibits the phosphorylation of constitu-
tively active EGFRvIII and its downstream signaling, may be com-
bined with sorafenib to enhance its antitumor effects. The present
study shows for the first time that the combination of sorafenib and
the monoclonal antibody CH12 can additively inhibit the growth of
HCC cells expressing EGFRvIII both in vitro and in vivo. Further-
more, we elucidated the possible mechanisms responsible for this
additive interaction.
Figure 4. Antitumor effects of sorafenib plus CH12 on Huh-7–EGFRvIII xenografts in established models. Huh-7–EGFRvIII cells (3 × 106)
were subcutaneously injected into 4- to 6-week-old nude mice when the tumors had reached a mean tumor volume of 100 mm3. (A and
B) Mice were treated with solvent control, sorafenib, CH12, or a combination of CH12 plus sorafenib. After 29 days, the mice were
sacrificed, and whole tumor tissues were isolated as described in Materials and Methods. (C) Data are expressed as mean tumor volumes.
(D) Data are expressed as the percentage inhibition of tumor growth. (E) Analysis of tumor weight. Columns, mean (n= 6). *P< .05 versus
control. **P < .05 versus sorafenib or CH12 treatment alone.
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Figure 5. Sorafenib plus CH12 treatment leads to the decreased growth of Huh-7–EGFRvIII xenograft tumors. (A) Tumor sections were
stained with Ki-67. (B) The cell proliferative index was assessed as the percentage of total cells that were Ki-67–positive in six randomly
selected high-power fields (×400) in xenografts from six mice of each group. (C) Tumor sections were immunostained with anti-CD34
antibody. Microvessel density values were analyzed by measuring the number of stained microvessels from six randomly selected fields
(×200) in xenografts from six mice of each group. (D) Qualitative analysis of tumor vascularization. Data are means ± SE. All of the data
were analyzed with the ANOVA. P < .05 was considered statistically significant.
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Figure 6. Sorafenib plus CH12 treatment leads to an increase in apoptosis of Huh-7–EGFRvIII xenograft tumors. Apoptotic cells were
detected using the TUNEL assay. The apoptotic index was assessed by the ratio of TUNEL-positive cells to the total number of cells
from six randomly selected high-power fields (×400) in xenografts from six mice of each group. Data are mean ± SE. All data were
analyzed by ANOVA. P < .05 was considered statistically significant.
Figure 7. Mechanisms of antitumor activity after treatment with sorafenib plus CH12. Established Huh-7–EGFRvIII xenografts treated with
PBS, sorafenib, CH12, or the combination were excised and prepared through homogenization in cell lysis buffer. Tumor lysates (20 μg)
were then subjected to SDS-PAGE and immunoblotted for total EGFR, p-EGFR (Tyr1068), total MEK, p-MEK, total ERK, p-ERK, total Akt,
p-Akt (Thr308), p-Akt (Ser473), total STAT3, p-STAT3, P27, and Bcl-XL, as indicated.
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Aprevious study reported that the combination of sorafenib (30mg/kg)
plus clodrolip or zoledronic acid could significantly induce HCC xeno-
graft tumor growth inhibition [28]. Here, our study showed that the
treatment of Huh-7–EGFRvIII xenografts with CH12 plus a low
concentration of sorafenib (10 mg/kg) resulted in significant tumor
growth inhibition of approximately 85.4%, which was more effective
than that of the single agents.
Many studies have shown that sorafenib inhibits Raf kinase and thus
blocks MEK/ERK signaling in HCC cells [29,30]. In this study, we
also found that p-ERK was inhibited by both sorafenib and CH12
alone in Huh-7–EGFRvIII and SMMC-7721 cells, but CH12 seemed
to promote sorafenib inhibition of theMEK/ERK pathway. Akt plays a
critical role in cell survival and acts as a mediator of phosphoinositide
3-kinase (PI3K) signaling [31]. Recently, it has been proposed that
Akt may be one of the main mediators of sorafenib resistance, although
several studies have produced controversial results. Fujimaki et al. [24]
revealed that sorafenib significantly decreased the levels of p-Akt
(Thr308) and increased the levels of p-Akt (Ser473) in both HepG2
and PLC/PRF/5 cells. In the present study, our data illustrate that
sorafenib alone or in combination with CH12 can downregulate the
levels of p-Akt (Thr308) both in Huh-7–EGFRvIII and in SMMC-
7721 cells. But sorafenib alone can obviously increase the levels of
p-Akt (Ser473) in Huh-7–EGFRvIII cells, although we did not find
the same trend in SMMC-7721 cells. We consider that the status of
p-Akt activation might not be the same in different types of HCC
cells. In addition, Thr308 is phosphorylated by PDK1, a key com-
ponent of PI3K signaling [32,33], whereas Ser473 is phosphorylated
by the elusive PDK2, which was proposed to be mTOR complex 2
including rictor and Sin1 [34]. Thus, we surmise that CH12 enhances
the antitumor effect of sorafenib at least partially through the PI3K/
AKT (Thr308) pathway. STAT3 has been implicated in the transcrip-
tion of genes that are associated with cell proliferation and survival, and
its constitutive activation has been associated with a number of human
epithelial cancers [35]. Recent reports have also indicated that STAT3
activation can be inhibited by sorafenib in glioblastoma and pancreatic
cells [21,36]. Here, we investigated the activation status of STAT3 in
Huh-7–EGFRvIII and SMMC-7721 cells or xenografts treated with
sorafenib and CH12 either singly or in combination. Intriguingly,
when sorafenib and CH12 were combined, the phosphorylation of
STAT3 was noticeably decreased. However, there was no obvious
down-regulation of p-STAT3 when both cell lines were treated with
sorafenib or CH12 alone.
Our previous research found that CH12 had the same epitope as
ch806 [37], which bound specifically to overexpressed and mutant
EGFR. A phase 1 clinical trial indicated that ch806 showed excellent
targeting to tumor sites in all patients, with no evidence of uptake by
normal tissues and no significant toxicity [38]. In conclusion, we sug-
gest that the combination of sorafenib plus CH12 is a candidate for
clinical applications, either to permit the use of a lower dosage or to
enhance clinical responses to sorafenib.
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